CHEST:中重度OSA与冠状动脉粥样斑块体积相关

2014-02-17 sd3212 dxy

虚拟组织学血管内超声(VH-IVUS)是一种血管内成像技术,可评估冠状动脉内粥样硬化斑块的特征。为了了解冠状动脉疾病患者中,阻塞性睡眠呼吸暂停(OSA)与其冠状动脉内粥样硬化斑块特征之间的联系,来自新加坡国立大学心脏中心心脏科的Lee博士等进行了一项研究,研究结果在线发表于2013年10月31日的CHEST杂志上。结果显示在患有冠状动脉疾病的患者中,中度至重度OSA是目标冠

虚拟组织学血管内超声(VH-IVUS)是一种血管内成像技术,可评估冠状动脉内粥样硬化斑块的特征。为了了解冠状动脉疾病患者中,阻塞性睡眠呼吸暂停(OSA)与其冠状动脉内粥样硬化斑块特征之间的联系,来自新加坡国立大学心脏中心心脏科的Lee博士等进行了一项研究,研究结果在线发表于2013年10月31日的CHEST杂志上。结果显示在患有冠状动脉疾病的患者中,中度至重度OSA是目标冠状动脉粥样斑块总体体积较大的独立相关因素。【原文下载】

该研究是一项前瞻性临床研究,其研究对象主要是经血管造影证实为患有冠状动脉疾病的患者,进行VH-IVUS检查、和以家中睡眠为主的睡眠研究,并测量整个目标冠状动脉内动脉粥样斑块的总体积,及其薄纤维帽粥样硬化斑块的发生率;此外,对无OSA、及合并轻度OSA患者,与合并中度~重度OSA患者之间指标的差异进行比较。


研究共招募了118例受试者,其中93例完成了研究,共有32 例(34.4%)被新诊断为轻度~重度OSA,其呼吸暂停低通气指数(AHI)均>15.与无OSA、及合并轻度OSA组患者相比,合并中度~重度OSA患者动脉粥样硬化斑块的总体积明显更大,并具有统计学意义上的显著性差异。

而且这种差异在对受试者年龄、体重指数、高血压糖尿病、吸烟、以及高脂血症等因素进行了统计学校正后依然存在。相反,两组受试者薄纤维帽粥样硬化斑块的发生率则分别为53.1%与54.2%,不具有显著性差异。

该研究结果显示,在患有冠状动脉疾病的患者中,中度至重度OSA是目标冠状动脉粥样斑块总体体积较大的独立相关因素。研究者认为,有必要在未来的研究中,进一步评估连续气道正压通气治疗对于此类患者动脉粥样斑块总体体积的影响。

原始出处:

Tan A, Hau W, Ho HH, Ghaem Maralani H, Loo G, Khoo SM, Tai BC, Richards AM, Ong P, Lee CH.OSA and Coronary Plaque Characteristics.Chest. 2014 Feb 1;145(2):322-30. doi: 10.1378/chest.13-1163.【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929204, encodeId=45a71929204dd, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Mar 08 20:18:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030692, encodeId=01ab20306923b, content=<a href='/topic/show?id=9f9533291dd' target=_blank style='color:#2F92EE;'>#动脉粥样斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33291, encryptionId=9f9533291dd, topicName=动脉粥样斑块)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Sat Nov 08 01:18:00 CST 2014, time=2014-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019783, encodeId=18eb2019e83fd, content=<a href='/topic/show?id=6c3ce629914' target=_blank style='color:#2F92EE;'>#粥样斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76299, encryptionId=6c3ce629914, topicName=粥样斑块)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Wed Oct 08 05:18:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050388, encodeId=93a420503883f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed May 21 18:18:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329999, encodeId=b767132999929, content=<a href='/topic/show?id=a91c5e92328' target=_blank style='color:#2F92EE;'>#斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57923, encryptionId=a91c5e92328, topicName=斑块)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Feb 19 00:18:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349732, encodeId=4c3d1349e3281, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Wed Feb 19 00:18:00 CST 2014, time=2014-02-19, status=1, ipAttribution=)]
    2014-03-08 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929204, encodeId=45a71929204dd, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Mar 08 20:18:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030692, encodeId=01ab20306923b, content=<a href='/topic/show?id=9f9533291dd' target=_blank style='color:#2F92EE;'>#动脉粥样斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33291, encryptionId=9f9533291dd, topicName=动脉粥样斑块)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Sat Nov 08 01:18:00 CST 2014, time=2014-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019783, encodeId=18eb2019e83fd, content=<a href='/topic/show?id=6c3ce629914' target=_blank style='color:#2F92EE;'>#粥样斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76299, encryptionId=6c3ce629914, topicName=粥样斑块)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Wed Oct 08 05:18:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050388, encodeId=93a420503883f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed May 21 18:18:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329999, encodeId=b767132999929, content=<a href='/topic/show?id=a91c5e92328' target=_blank style='color:#2F92EE;'>#斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57923, encryptionId=a91c5e92328, topicName=斑块)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Feb 19 00:18:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349732, encodeId=4c3d1349e3281, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Wed Feb 19 00:18:00 CST 2014, time=2014-02-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929204, encodeId=45a71929204dd, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Mar 08 20:18:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030692, encodeId=01ab20306923b, content=<a href='/topic/show?id=9f9533291dd' target=_blank style='color:#2F92EE;'>#动脉粥样斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33291, encryptionId=9f9533291dd, topicName=动脉粥样斑块)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Sat Nov 08 01:18:00 CST 2014, time=2014-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019783, encodeId=18eb2019e83fd, content=<a href='/topic/show?id=6c3ce629914' target=_blank style='color:#2F92EE;'>#粥样斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76299, encryptionId=6c3ce629914, topicName=粥样斑块)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Wed Oct 08 05:18:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050388, encodeId=93a420503883f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed May 21 18:18:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329999, encodeId=b767132999929, content=<a href='/topic/show?id=a91c5e92328' target=_blank style='color:#2F92EE;'>#斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57923, encryptionId=a91c5e92328, topicName=斑块)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Feb 19 00:18:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349732, encodeId=4c3d1349e3281, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Wed Feb 19 00:18:00 CST 2014, time=2014-02-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1929204, encodeId=45a71929204dd, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Mar 08 20:18:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030692, encodeId=01ab20306923b, content=<a href='/topic/show?id=9f9533291dd' target=_blank style='color:#2F92EE;'>#动脉粥样斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33291, encryptionId=9f9533291dd, topicName=动脉粥样斑块)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Sat Nov 08 01:18:00 CST 2014, time=2014-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019783, encodeId=18eb2019e83fd, content=<a href='/topic/show?id=6c3ce629914' target=_blank style='color:#2F92EE;'>#粥样斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76299, encryptionId=6c3ce629914, topicName=粥样斑块)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Wed Oct 08 05:18:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050388, encodeId=93a420503883f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed May 21 18:18:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329999, encodeId=b767132999929, content=<a href='/topic/show?id=a91c5e92328' target=_blank style='color:#2F92EE;'>#斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57923, encryptionId=a91c5e92328, topicName=斑块)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Feb 19 00:18:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349732, encodeId=4c3d1349e3281, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Wed Feb 19 00:18:00 CST 2014, time=2014-02-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1929204, encodeId=45a71929204dd, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Mar 08 20:18:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030692, encodeId=01ab20306923b, content=<a href='/topic/show?id=9f9533291dd' target=_blank style='color:#2F92EE;'>#动脉粥样斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33291, encryptionId=9f9533291dd, topicName=动脉粥样斑块)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Sat Nov 08 01:18:00 CST 2014, time=2014-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019783, encodeId=18eb2019e83fd, content=<a href='/topic/show?id=6c3ce629914' target=_blank style='color:#2F92EE;'>#粥样斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76299, encryptionId=6c3ce629914, topicName=粥样斑块)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Wed Oct 08 05:18:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050388, encodeId=93a420503883f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed May 21 18:18:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329999, encodeId=b767132999929, content=<a href='/topic/show?id=a91c5e92328' target=_blank style='color:#2F92EE;'>#斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57923, encryptionId=a91c5e92328, topicName=斑块)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Feb 19 00:18:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349732, encodeId=4c3d1349e3281, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Wed Feb 19 00:18:00 CST 2014, time=2014-02-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1929204, encodeId=45a71929204dd, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Mar 08 20:18:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030692, encodeId=01ab20306923b, content=<a href='/topic/show?id=9f9533291dd' target=_blank style='color:#2F92EE;'>#动脉粥样斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33291, encryptionId=9f9533291dd, topicName=动脉粥样斑块)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Sat Nov 08 01:18:00 CST 2014, time=2014-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019783, encodeId=18eb2019e83fd, content=<a href='/topic/show?id=6c3ce629914' target=_blank style='color:#2F92EE;'>#粥样斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76299, encryptionId=6c3ce629914, topicName=粥样斑块)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Wed Oct 08 05:18:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050388, encodeId=93a420503883f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed May 21 18:18:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329999, encodeId=b767132999929, content=<a href='/topic/show?id=a91c5e92328' target=_blank style='color:#2F92EE;'>#斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57923, encryptionId=a91c5e92328, topicName=斑块)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Feb 19 00:18:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349732, encodeId=4c3d1349e3281, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Wed Feb 19 00:18:00 CST 2014, time=2014-02-19, status=1, ipAttribution=)]
    2014-02-19 bioon3

相关资讯

Diabetes Care:阻塞性睡眠呼吸暂停影响胰岛素敏感性和分泌

  美国学者的一项研究表明,在青年消瘦男性中,阻塞性睡眠呼吸暂停(OSA)与胰岛素抵抗和胰岛素分泌代偿性升高具有相关性。论文于2012年8月21日在线发表于《糖尿病护理》(Diabetes Care)杂志。   此项前瞻性研究共纳入52例接受多导睡眠图和晨起口服糖耐量试验的消瘦健康男性。依据种族糖尿病风险和糖尿病家族史对受试者进行分层。选取无OSA的20例对照男性和伴OSA的12例男性

HEART RHYTHM:阻塞性睡眠呼吸暂停升高房颤消融后复发率

  日本学者的一项研究表明,伴有未治疗阻塞性睡眠呼吸暂停(OSA)的患者房颤射频消融后复发率较高;在OSA患者中适宜的持续气道正压(CPAP)治疗与房颤复发率降低相关。论文于2012年11月26日在线发表于《心律》(Heart Rhythm)杂志。   此项研究共纳入153例因耐药性房颤而接受广泛环肺静脉电隔离的患者[(男性128例,年龄为(60±9)岁]。在射频消融1周后进行标

Chest:限盐饮食或可缓解睡眠呼吸暂停

  澳大利亚昆士兰大学医学院Pimenta及其同事进行的一项研究表明,对于顽固性高血压和醛固酮增多症患者,膳食中盐的摄入量与其阻塞性睡眠呼吸暂停(OSA)严重程度有关。   OSA是高血压病(尤其是顽固性高血压病)与心血管疾病较强的独立危险因素,顽固性高血压患者的OSA患病率普遍较高,这一现象与此类患者醛固酮水平、盐摄入量以及血压的盐敏感性较高有关。   研究者使用夜间多导睡眠仪监

Diabetes Care:阻塞性睡眠呼吸暂停应警惕糖尿病肾病

DiabetesCare 2013年9月23日在线版发布了英国伯明翰大学AbdA.Tahrani等开展的一项队列研究,研究显示,伴阻塞性睡眠呼吸暂停(OSA)的2型糖尿病患者发生肾病的风险是无糖尿病者的2.64倍。 在该研究中,糖尿病肾病(DN)定义为:出现白蛋白尿或估算肾小球滤过率(eGFR)<60ml/min/1.73m2;OSA定义为:呼吸暂停低通气指数(AHI)≥5次/h。在纳入研

JAMA:合并OSA的顽固性高血压患者持续气道正压通气可获益

超过70%的难治性高血压患者有阻塞性睡眠呼吸暂停(OSA),但鲜有证据表明持续气道正压通气(CPAP)对顽固性高血压(resistant hypertension)患者血压的影响。近期西班牙一项研究表明,在合并OSA的顽固性高血压患者中,CPAP治疗12周可使其24小时平均血压和舒张压以及夜间勺型高血压模式有所改善。相关论文2013年12月11日在线发表于《美国医学会杂志》(JAMA)。

阻塞性睡眠呼吸暂停与血压难控制相关

巴尔的摩——根据一项随机对照试验的数据,尽管成人重度阻塞性睡眠呼吸暂停(OSA)患者往往使用多种抗高血压药物,但其难治性高血压患病率仍显著高于中度OSA患者。 克利夫兰医院的Harneet Walia医生及其同事回顾了参与HeartBEAT(呼吸暂停治疗中的心脏生物学标记物评估)研究的4个中心318例患者的基线数据。该试验将患者随访分配到接受关于健康生活方式和睡眠规划的教育项目组或教育项